A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE MASS BALANCE, METABOLISM AND EXCRETION OF [14C]PF-07321332 IN HEALTHY MALE PARTICIPANTS
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 20 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Jan 2022 New trial record